Revolution Medicines, Inc. (RVMDW)Redwood City, United States | NasdaqGS
8.96 USD
-0.40
(-4.274%) ⇩
(July 13, 2026, 3:57 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:36 a.m. EDT
The immediate outlook is severely compromised by a massive insider sale, with an officer proposing to offload 3.39 million shares, signaling extreme lack of confidence at the highest level. Fundamentally, the business is in distress, burning through significant cash reserves with negative free cash flow and operating cash flow, while posting substantial losses on both assets and equity. The balance sheet, though currently bolstered by cash, cannot sustain these burn rates indefinitely without further dilution or capital raising. There is no dividend to provide income, and the price action shows no recovery, trading near its 52-week lows. This combination of aggressive insider selling, deep operational losses, and a depleted cash runway creates a compelling case to avoid the stock entirely in the near term. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 29.153 |
| Beta | 1.38 |
| Website | https://www.revmed.com |
| Attribute | Value |
|---|---|
| Address1 | 700 Saginaw Drive |
| Ask | 0.3899 |
| Ask Size | 2 |
| Beta | 1.376 |
| Bid | 0.3517 |
| Bid Size | 20 |
| Book Value | 7.493 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.96 |
| Current Ratio | 6.795 |
| Custom Price Alert Confidence | HIGH |
| Day High | 9.18 |
| Day Low | 8.57 |
| Debt To Equity | 29.153 |
| Display Name | Revolution Medicines |
| Ebitda | -1,378,393,984 |
| Ebitda Margins | 0.0 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 9.18 |
| Fifty Two Week High Change | -0.22000027 |
| Fifty Two Week High Change Percent | -0.02396517 |
| Fifty Two Week Low | 8.57 |
| Fifty Two Week Low Change | 0.39000034 |
| Fifty Two Week Low Change Percent | 0.045507625 |
| Fifty Two Week Range | 8.57 - 9.18 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,783,690,200,000 |
| Float Shares | 194,111,200 |
| Free Cashflow | -606,370,880 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 883 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -1,125,553,024 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,023-11-17 |
| Language | en-US |
| Long Business Summary | Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. |
| Long Name | Revolution Medicines, Inc. |
| Market | us_market |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_283775412 |
| Net Income To Common | -1,371,700,992 |
| Open | 0.386 |
| Operating Cashflow | -1,057,470,976 |
| Operating Margins | 0.0 |
| Phone | 650 481 6801 |
| Previous Close | 9.36 |
| Price Hint | 2 |
| Price To Book | 1.1957828 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.589 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.39999962 |
| Regular Market Change Percent | -4.2735004 |
| Regular Market Day High | 9.18 |
| Regular Market Day Low | 8.57 |
| Regular Market Day Range | 8.57 - 9.18 |
| Regular Market Open | 0.386 |
| Regular Market Previous Close | 9.36 |
| Regular Market Price | 8.96 |
| Regular Market Time | 1,783,972,678 |
| Regular Market Volume | 38,676 |
| Return On Assets | -0.3753 |
| Return On Equity | -0.76672995 |
| Sand P52 Week Change | 0.20847368 |
| Sector | |
| Sector Key | |
| Short Name | Revolution Medicines, Inc. Warr |
| Source Interval | 15 |
| State | CA |
| Symbol | RVMDW |
| Total Cash | 1,908,083,968 |
| Total Cash Per Share | 8.975 |
| Total Debt | 437,272,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 38,676 |
| Website | https://www.revmed.com |
| Zip | 94,063 |